Latest Pharmaceuticals News

AFT Pharmaceuticals has reported record revenue of NZD 208 million for FY25, driven by strong Australasian sales and a recovery in Asia and international markets. The company is targeting NZD 300 million in revenue by FY27, supported by an expanded R&D pipeline and ongoing geographic diversification.

AFT Pharmaceuticals reported a 6% increase in revenue to NZ$208 million for the year ending March 2025, but net profit fell 23%, prompting a modest final dividend declaration.

Mayne Pharma has firmly rejected Cosette Pharmaceuticals’ assertion of a Material Adverse Change that could derail their acquisition scheme, insisting the deal process continues as planned.

Island Pharmaceuticals has raised $3.6 million through a strategic share placement to advance its lead antiviral drug ISLA-101’s clinical development and broaden its asset portfolio ahead of pivotal Phase 2a/b trial results.

LTR Pharma has appointed Associate Professor Darren Katz, a leading urologist and erectile dysfunction expert, to its Scientific Advisory Board, aiming to fast-track the development and commercialization of its innovative nasal spray treatments SPONTAN and ROXUS.

ASPI Isotopes Inc. has agreed to acquire Renergen Limited in an all-share deal, creating a vertically integrated global entity focused on critical materials for semiconductors, medical isotopes, and green energy. The transaction addresses Renergen’s liquidity challenges and positions the combined company for growth across multiple strategic sectors.

Whitefield Industrials Limited reported a 10% increase in core operating profit for the year ended March 2025, outperforming its benchmark with a 7.5% portfolio return and raising fully franked dividends to 10.5 cents per share.

Clarity Pharmaceuticals has initiated its second registrational Phase III AMPLIFY trial for the Cu-SAR-bisPSMA PET imaging agent targeting biochemical recurrence of prostate cancer. The multi-centre study aims to generate critical data supporting FDA approval and could redefine prostate cancer diagnostics.

Avecho Biotechnology has expanded its pivotal Phase III clinical trial for a CBD insomnia treatment by adding new recruitment sites and partnering with pharmaceutical giant Sandoz to boost patient enrolment and regulatory progress.

LTR Pharma has expanded patient access to its fast-acting erectile dysfunction treatment SPONTAN by partnering with TerryWhite Chemmart’s extensive pharmacy network, marking a significant step in its commercial rollout and regulatory strategy.

Mayne Pharma has sent out the Scheme Booklet to shareholders, marking a key step in the proposed acquisition by Cosette. The booklet includes critical details to guide shareholder decisions ahead of the upcoming Scheme Meeting.

Recce Pharmaceuticals has successfully raised A$8.4 million through an entitlement offer and placement to fund pivotal Phase 3 clinical trials, advancing its synthetic anti-infective pipeline towards commercialisation in 2026.